Description
Original Release Date: January 13, 2026
Expiration Date: January 13, 2028
Target Audience
This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of immunoglobulin therapy and specialty biologics.
Faculty
| Faculty | Conflicts of Interest |
| Leslie Myers, PharmD, IgCP® Integrated Clinical Services Manager | Has no relevant financial relationships |
| Lucas Felipe Bastos Horta, MD Emory School of Medicine | Has no relevant financial relationships |
| Elena Perez, MD, PhD Allergist & Immunologist | Consultant/Advisor/Speaker: ADMA, CSL Behring, Grifols |
| Amy Clarke, DNP, RN, IgCN® Chief Clinical Officer | Has no relevant financial relationships |
| Christie Fisher, MSN, MBA, RN, CRNI, IgCN® National Director, Nursing | Has no relevant financial relationships |
| Amy Ehlers, BS, PharmD, CSP, IgCP® Vice President, Clinical Programs | Consultant/Advisor/Speaker: Octapharma |
Educational Objectives
Upon completion of this activity, participants should be able to:
- Differentiate between IVIg and SCIg products and describe how formulation differences influence infusion strategies, tolerability, and clinical decision-making
- Apply current evidence and best practices in the use of Ig therapy for neuromuscular disorders and primary immunodeficiencies, including patient selection and individualized dosing approaches
- Implement Ig administration standards for both IVIg and SCIg in accordance with national guidelines, infusion protocols, and safety monitoring requirements
- Identify key safety risks and mitigation strategies related to Ig therapy, including boxed warnings, IV access considerations, and emerging clinical issues impacting interprofessional practice
